These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7938951)

  • 21. Oxytocin, vasopressin, and the neurogenetics of sociality.
    Donaldson ZR; Young LJ
    Science; 2008 Nov; 322(5903):900-4. PubMed ID: 18988842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct.
    Hus-Citharel A; Bodineau L; Frugière A; Joubert F; Bouby N; Llorens-Cortes C
    Endocrinology; 2014 Nov; 155(11):4483-93. PubMed ID: 25157454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational vasopressin receptor modulators in the pipeline.
    Favory R; Salgado DR; Vincent JL
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1119-31. PubMed ID: 19589090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of cellular electrophysiological actions of vasopressin.
    Raggenbass M
    Eur J Pharmacol; 2008 Apr; 583(2-3):243-54. PubMed ID: 18280467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vasopressin and receptor].
    Marumo F
    Nihon Rinsho; 1981 Sep; 39(9):2970-4. PubMed ID: 6279927
    [No Abstract]   [Full Text] [Related]  

  • 26. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin.
    Ball SG
    Ann Clin Biochem; 2007 Sep; 44(Pt 5):417-31. PubMed ID: 17761027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyponatremia in cirrhosis: from pathogenesis to treatment.
    Ginés P; Berl T; Bernardi M; Bichet DG; Hamon G; Jiménez W; Liard JF; Martin PY; Schrier RW
    Hepatology; 1998 Sep; 28(3):851-64. PubMed ID: 9731583
    [No Abstract]   [Full Text] [Related]  

  • 28. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.
    Aoyagi T; Izumi Y; Hiroyama M; Matsuzaki T; Yasuoka Y; Sanbe A; Miyazaki H; Fujiwara Y; Nakayama Y; Kohda Y; Yamauchi J; Inoue T; Kawahara K; Saito H; Tomita K; Nonoguchi H; Tanoue A
    Am J Physiol Renal Physiol; 2008 Jul; 295(1):F100-7. PubMed ID: 18448596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of potent and specific vasopressin antagonists.
    Sawyer WH; Manning M
    Kidney Int Suppl; 1988 Oct; 26():S34-7. PubMed ID: 3059031
    [No Abstract]   [Full Text] [Related]  

  • 30. Vasopressin antagonists: present and future.
    Hofbauer KG; Mah SC
    Kidney Int Suppl; 1987 Aug; 21():S76-82. PubMed ID: 3306108
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurohypophysial peptides: gatekeepers in the amygdala.
    Pittman QJ; Spencer SJ
    Trends Endocrinol Metab; 2005 Oct; 16(8):343-4. PubMed ID: 16109490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.
    Petersen MB
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):96-103. PubMed ID: 16918709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: from central release to sites of action.
    Bosch OJ; Neumann ID
    Horm Behav; 2012 Mar; 61(3):293-303. PubMed ID: 22100184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biological basis for social recognition: CD38 controls oxytocin secretion].
    Higashida H
    Tanpakushitsu Kakusan Koso; 2007 Nov; 52(14):1832-9. PubMed ID: 18018634
    [No Abstract]   [Full Text] [Related]  

  • 35. [Nephrogenic diabetes insipidus: Pathogenesis, pathophysiology, and therapy].
    Ota E; Sasaki S
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():528-30. PubMed ID: 16523948
    [No Abstract]   [Full Text] [Related]  

  • 36. Involvement of prolactin, vasopressin and opioids in post-ictal antinociception induced by electroshock in rats.
    Portugal-Santana P; Doretto MC; Tatsuo MA; Duarte ID
    Brain Res; 2004 Apr; 1003(1-2):1-8. PubMed ID: 15019557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of antagonists of vasopressin in studies of its physiological functions.
    Sawyer WH; Manning M
    Fed Proc; 1985 Jan; 44(1 Pt 1):78-80. PubMed ID: 2981734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopressin antagonists.
    Jard S
    Adv Nephrol Necker Hosp; 1987; 16():1-15. PubMed ID: 2949544
    [No Abstract]   [Full Text] [Related]  

  • 39. The contributions of oxytocin and vasopressin pathway genes to human behavior.
    Ebstein RP; Knafo A; Mankuta D; Chew SH; Lai PS
    Horm Behav; 2012 Mar; 61(3):359-79. PubMed ID: 22245314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diurnal rhythm in vasopressin V1a receptor expression in the suprachiasmatic nucleus is not dependent on vasopressin.
    Young WS; Kovács K; Lolait SJ
    Endocrinology; 1993 Aug; 133(2):585-90. PubMed ID: 8344200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.